NSCLC : Bulletin #3
Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment of BRAF V600-positive advanced NSCLC; Takeda's Alunbrig (brigatinib) being granted accelerated approval in the US for the treatment of patients with metastatic ALK-positive NSCLC who have progressed on or are intolerant to Xalkori (crizotinib; Pfizer); the Phase III ALEX study demonstrating Roche’s Alecensa (alectinib) to be superior to Xalkori in terms of progression-free survival (PFS) in the first-line treatment of ALK-positive NSCLC; and AbbVie’s PARP inhibitor, veliparib, failing to meet its primary endpoint of overall survival (OS) in a Phase III trial in NSCLC.
Reasons to Purchase
How do KOLs view the EU approval of Novartis’s Mekinist in combination with Tafinlar for the treatment of BRAF V600-positive advanced NSCLC?
Where do KOLs see Mekinist plus Tafinlar fitting into the NSCLC treatment algorithm?
What factors could curtail the use of Mekinist in combination with Tafinlar?
How do KOLs view the US approval of Takeda's Alunbrig and data from the ALTA trial?
Where will Alunbrig be best positioned in the NSCLC treatment algorithm?
How do KOLs view the positive outcome from the ALEX trial of Roche’s Alecensa and what will determine its success in first-line therapy?
To what extent will Alecensa be used in the first-line treatment of ALK-positive NSCLC?
How is the second-line treatment of ALK-positive NSCLC likely to evolve in light of recent events?
How do KOLs view the Phase III failure of AbbVie’s veliparib and the future of PARP inhibitors in NSCLC?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook